TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Status:
Recruiting
Trial end date:
2021-12-14
Target enrollment:
Participant gender:
Summary
Interferon (IFN) lambda is one of the fundamental responses of the innate immune system.
Peginterferon lambda is a long-acting form that has been studied extensively in human trials
in viral hepatitis, confirming it safety and tolerability. It is particularly attractive for
consideration in the use of acute respiratory illness due to the high expression of the
lambda receptor in lung epithelia. We propose to evaluate peginterferon-lambda in ambulatory
patients with mild to moderate COVID-19.